Recently, the advances in surgical and medical management, such as intravitreal anti-VEGF (vascular endothelial growth factor) therapy, provide more options for retinal diseases [2,3], but are still invalid in many conditions especially when the disease is accompanied with retinal cell loss. The gene discussed is VEGFA; the disease is Abnormal retinal morphology.